In the absence of broadly recognized radiographic recommendations, the author proposes that the OBrien rule-of-thumb guidelines 105 (as noted above) be introduced until a more comprehensive study can establish other radiographic diagnostic criteria (or confirm these)
How Your Body Adapts to Semaglutide Over Time As you continue with semaglutide treatment, your body will gradually adapt to the medication
Brand names such as Wegovy, Ozempic, and the newly FDA-approved Wegovy pill establish semaglutide as a strong choice for both weight management and type 2 diabetes
Seek urgent medical attention (contact 999 or attend A&E) if you experience: Severe, persistent abdominal pain, particularly if accompanied by fever, vomiting, or inability to pass stools or wind Blood in your stools (red blood or black, tarry stools) Signs of severe dehydration: extreme thirst, dark urine, dizziness, confusion, or reduced urine output Persistent vomiting preventing fluid or medication intake Symptoms suggesting pancreatitis: severe upper abdominal pain radiating to the back, often with nausea and vomiting (if pancreatitis is suspected, stop taking your GLP-1 medication immediately) Right upper abdominal pain with fever, yellowing of skin/eyes, dark urine or pale stools (possible gallbladder problems) Contact NHS 111 or your GP within 24-48 hours if: Diarrhoea persists beyond 7 days without improvement You're passing more than 6 loose stools daily Bowel symptoms are significantly impacting your quality of life, work, or daily activities You're unable to maintain adequate nutrition or hydration You develop new symptoms such as unexplained weight loss (beyond expected therapeutic effect), persistent fever, or night sweats Symptoms worsen rather than improve over time Routine review is appropriate if: Mild to moderate symptoms persist but are manageable You're uncertain whether symptoms are medication-related You wish to discuss dose adjustments or alternative management strategies GLP-1 medications are associated with recognised gastrointestinal risks including pancreatitis, gallbladder disease, and rarely, intestinal obstruction
Your provider might recommend gradually reducing your dose week by week over the course of several weeks
doi:10.3389/fneur.2022.844697 Hu EH, Tsai ML, Lin Y, Chou TS, Chen TH
